Molecular mechanisms of glioma cell migration and invasion - PubMed (original) (raw)
Review
Molecular mechanisms of glioma cell migration and invasion
Tim Demuth et al. J Neurooncol. 2004 Nov.
Abstract
Gliomas are the most common intracranial tumors. In the US, approximately 15,000 patients die with glioblastoma per year (CBTRUS 2002). Despite modern diagnostics and treatments the median survival time does not exceed 15 months. However, it has long been observed that after surgical removal, tumors recur predominantly within 1 cm of the resection cavity. This is mainly due to the fact that at the time of surgery, cells from the bulk tumor have already invaded normal brain tissue. Decades ago Matsukado showed that more than 50% of untreated brain tumors had already reached the contralateral hemisphere (J Neurosurg 18: 636-644, 1961). Therefore one of the most important hallmarks of malignant gliomas is their invasive behavior. Dandy already recognized the highly invasive characteristics of this tumor type and performed hemispherectomy in patients with preoperative hemiplegia (J Am Med Assoc 90: 823-825, 1928). Despite his and others' heroic efforts, recurrence was detected as early as 3 months after surgery (Bell, LJ: J Neurosurg 6: 285-293, 1949), leading to the discontinuation of this radical approach. Diffuse gliomas remain a particularly challenging clinical management problem. Over the last 20 years no significant increase in survival of patients suffering from this disease has been achieved. Even drugs directed against newly identified targets like MMPs or angiogenesis-related targets fail to increase survival duration (Tonn, Goldbrunner: Acta Neurochir Suppl 88: 163-167, 2003) Furthermore, anti-angiogenic drugs have been shown to increase glioma invasiveness, finally leading to gliomatosis cerebri. (Lamszus et al.: Acta Neurochir Suppl 88: 169-177, 2003). In this review we focus on the main features which may underlie the invasive phenotype of human gliomas, and offer a biological basis for optimism towards therapeutic advances to come.
Similar articles
- Cost of migration: invasion of malignant gliomas and implications for treatment.
Giese A, Bjerkvig R, Berens ME, Westphal M. Giese A, et al. J Clin Oncol. 2003 Apr 15;21(8):1624-36. doi: 10.1200/JCO.2003.05.063. J Clin Oncol. 2003. PMID: 12697889 Review. - Silencing hypoxia-inducible factor-1alpha inhibits cell migration and invasion under hypoxic environment in malignant gliomas.
Fujiwara S, Nakagawa K, Harada H, Nagato S, Furukawa K, Teraoka M, Seno T, Oka K, Iwata S, Ohnishi T. Fujiwara S, et al. Int J Oncol. 2007 Apr;30(4):793-802. Int J Oncol. 2007. PMID: 17332917 - Brain tumor cell invasion, anatomical and biological considerations.
Thorsen F, Tysnes BB. Thorsen F, et al. Anticancer Res. 1997 Nov-Dec;17(6B):4121-6. Anticancer Res. 1997. PMID: 9428345 Review. - Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro.
Huang Q, Zhang QB, Dong J, Wu YY, Shen YT, Zhao YD, Zhu YD, Diao Y, Wang AD, Lan Q. Huang Q, et al. BMC Cancer. 2008 Oct 22;8:304. doi: 10.1186/1471-2407-8-304. BMC Cancer. 2008. PMID: 18940013 Free PMC article. - PTEN gene transfer suppresses the invasive potential of human malignant gliomas by regulating cell invasion-related molecules.
Furukawa K, Kumon Y, Harada H, Kohno S, Nagato S, Teraoka M, Fujiwara S, Nakagawa K, Hamada K, Ohnishi T. Furukawa K, et al. Int J Oncol. 2006 Jul;29(1):73-81. Int J Oncol. 2006. PMID: 16773187
Cited by
- Concurrent Oncolysis and Neurolesion Repair by Dual Gene-Engineered hNSCs in an Experimental Model of Intraspinal Cord Glioblastoma.
Zeng X, Ropper AE, Aljuboori Z, Yu D, Teng TW, Kabatas S, Usuga E, Anderson JE, Teng YD. Zeng X, et al. Cells. 2024 Sep 11;13(18):1522. doi: 10.3390/cells13181522. Cells. 2024. PMID: 39329707 Free PMC article. - Prognostic relevance and validation of ARPC1A in the progression of low-grade glioma.
Dai J, Gao J, Dong H. Dai J, et al. Aging (Albany NY). 2024 Jun 19;16(14):11162-11184. doi: 10.18632/aging.205952. Epub 2024 Jun 19. Aging (Albany NY). 2024. PMID: 39012280 Free PMC article. - ODF3B affects the proliferation and apoptosis of glioma via the JAK/STAT pathway.
Luan XZ, Yuan SX, Chen XJ, Zhou YR, Tang H, Li JQ, Jiang G, Yang LX, Luo MW, Tian JJ, Wen YQ, Zhang WY, Chen LG, Xiang W, Zhou J. Luan XZ, et al. Am J Cancer Res. 2024 Mar 15;14(3):1419-1432. doi: 10.62347/GHKF1995. eCollection 2024. Am J Cancer Res. 2024. PMID: 38590411 Free PMC article. - Peritumoral brain zone in glioblastoma: biological, clinical and mechanical features.
Ballestín A, Armocida D, Ribecco V, Seano G. Ballestín A, et al. Front Immunol. 2024 Feb 29;15:1347877. doi: 10.3389/fimmu.2024.1347877. eCollection 2024. Front Immunol. 2024. PMID: 38487525 Free PMC article. Review. - High-Resolution Microscopic Characterization of Tunneling Nanotubes in Living U87 MG and LN229 Glioblastoma Cells.
Matejka N, Amarlou A, Neubauer J, Rudigkeit S, Reindl J. Matejka N, et al. Cells. 2024 Mar 6;13(5):464. doi: 10.3390/cells13050464. Cells. 2024. PMID: 38474428 Free PMC article.
References
- Cell. 1992 Aug 7;70(3):389-99 - PubMed
- Science. 2001 Nov 23;294(5547):1708-12 - PubMed
- Cell. 1991 Jul 12;66(1):107-19 - PubMed
- J Neurooncol. 2002 Dec;60(3):213-26 - PubMed
- J Cell Biol. 1997 Dec 29;139(7):1873-84 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical